At a glance
- Originator Fujisawa
- Class Antibacterials; Oligopeptides; Peptide antibiotics; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 18 May 2001 Discontinued-Preclinical for Bacterial infections in Japan (Unknown route)
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 03 May 1995 New profile